Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BI 836826 |
| Synonyms | |
| Therapy Description |
BI 836826 (MAb 37.1) is a monoclonal antibody that binds to CD37, resulting in anti-tumor immune response and tumor cell death (PMID: 26271483, PMID: 32172489). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BI 836826 | MAb 37.1|BI836826|BI-836826 | CD37 Antibody 9 | BI 836826 (MAb 37.1) is a monoclonal antibody that binds to CD37, resulting in anti-tumor immune response and tumor cell death (PMID: 26271483, PMID: 32172489). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01296932 | Phase I | BI 836826 | BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) | Completed | FRA | DEU | BEL | 0 |